CSPI on FDA advisory committees
This article was originally published in The Tan Sheet
Executive Summary
FDA should "immediately reform the process of choosing members of advisory committees" and end the "promiscuous use of scientists with conflicts of interest," the Center for Science in the Public Interest says in a FDL-1March 10 letter to Acting Commissioner Lester Crawford, PhD. The letter closely follows a CSPI investigation finding that 10 of the 32 advisory committee members during the February meeting on COX-2 inhibitors had financial ties to Pfizer, Merck and Novartis (1"The Tan Sheet" March 7, 2005, p. 15). FDA also should "limit the number of panel members with any industry ties to no more than half the committee," the letter asserts. A list of proposed advisory panelists and their biographies should be posted no later than 30 days before the meeting and "not within the last 72 hours as is presently the case." The public should then be given 20 days in which to comment on the proposed roster, CSPI says...
You may also be interested in...
FDA Waiver Of COX-2 Panel Conflicts Draws More Attention On The Hill
FDA advisory committee votes in favor of continued availability of COX-2s in the U.S. are "tainted" due to conflicts of interest among panelists, according to a Feb. 25 letter from Senate Finance Committee Chairman Chuck Grassley (R-Iowa)
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.